PQLC1 CRISPR/Cas9 KO Plasmid (h): sc-413347
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PQLC1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PQLC1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PQLC1 CRISPR/Cas9 KO Plasmid (h) | sc-413347 | 20 µg | $397.00 |
Overview
PQLC1 encodes a lysosomal membrane transporter implicated in the efflux of cationic amino acids from the lysosomal lumen to the cytosol, linking lysosomal amino acid recycling to broader cellular metabolic homeostasis. By influencing lysosome-dependent nutrient sensing and lysosomal export of basic amino acids, PQLC1 can modulate pathways tied to autophagy, proteostasis, and stress adaptation. Altered lysosomal transport and amino acid handling are recurrent features of neurodegeneration, cancer metabolism, and inherited lysosome-related disorders, making PQLC1 a useful node for mechanistic studies. Functional perturbation of PQLC1 helps dissect how lysosomal solute transport interfaces with signaling networks that respond to nutrient availability.
PQLC1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the PQLC1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the PQLC1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the PQLC1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PQLC1 protein expression.
This CRISPR knockout system enables efficient generation of PQLC1-deficient cell models for investigation of PQLC1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting PQLC1 exon(s) critical for PQLC1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple PQLC1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PQLC1 CRISPR/Cas9 KO Plasmid (h) and PQLC1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the PQLC1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PQLC1 HDR Plasmid (h) and PQLC1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by PQLC1 homology arms to support homology-directed repair at defined PQLC1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.